Nuvation Bio Inc.
NYSE:NUVBBiotechnology
+$0.06 today
- Market cap
- $1.33B
- Beta
- 1.56
- P/E (TTM)
- -12.8
- EPS (TTM)
- -$0.42
Volume 5.96M
Average 4.07M
NUVB EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Nuvation Bio Inc.NYSE: NUVB
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA remains negative
Q2 FY2026 EBITDA was -$55.55M, compared with -$58.23M a year earlier. Trailing-twelve-month EBITDA was -$127.04M.
Context
- EBITDA amounted to 300.8% of revenue in FY2025, down 6900.0 pp from a year earlier.
- EBITDA grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 10 analysts of -$127.69M (+32.5%) for the fiscal year ending Dec 2026, a slowdown from the +66.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$55.55M-539.4% QoQ
- Last fiscal yearDec 2025
- -$189.21M+66.6% YoY
- LTMJun 2026
- -$127.04M+36.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +4.6% | +32.7% | +28.1 pp |
| 1 year | +66.6% | +32.5% | -34.1 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (189.21M) USD
- Year-over-year change
- +66.6%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (189.21M) | +66.6% |
| FY2024 | 2024-12-31 | (566.92M) | -650.1% |
| FY2023 | 2023-12-31 | (75.58M) | +27.3% |
| FY2022 | 2022-12-31 | (104M) | -20.0% |
| FY2021 | 2021-12-31 | (86.66M) | — |
EBITDA vs competitors
How NUVB compares with its peers on the latest reported figures
- NUVB's LTM Jun 2026 EBITDA of -$127.04M is the 3rd highest of the 11 companies compared; the peer median is -$206.69M.
- Its year-over-year change of +36.8% is the 2nd highest of 11, against a peer median of -24.7%.
- EBITDA amounts to 74.8% of revenue for NUVB, versus a peer median of 520.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $188.22M | +117.6% | — | 60.4% | |
| LTM Mar 2026 | -$112.45M | -48.6% | — | 520.3% | |
| LTM Jun 2026 | -$127.04M | +36.8% | — | 74.8% | |
| LTM Mar 2026 | -$129.14M | +6.4% | — | 713.8% | |
| LTM Sep 2026 | -$138.65M | +34.7% | — | 204.3% | |
| LTM Sep 2026 | -$200.94M | -29.7% | — | — | |
| LTM Jun 2026 | -$212.44M | -19.8% | — | — | |
| LTM Mar 2026 | -$274.24M | -55.5% | — | 527.0% | |
| LTM Sep 2026 | -$305.37M | -38.1% | — | 272652.7% | |
| LTM Jun 2026 | -$367.57M | -7.9% | — | 516.8% | |
| LTM Jun 2026 | -$393.82M | -87.1% | — | — | |
| Peer median (excluding NUVB) | -$206.69M | -24.7% | — | 520.3% | |
Competitors are the stored peer set for NUVB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 7.87M | 62.9M |
| Cost of Revenue | 0 | 0 | 0 | 7.08M | 8.44M |
| Gross Profit | 0 | 0 | 0 | 795K | 54.46M |
| Gross Margin | — | — | — | 10.1% | 86.6% |
| Research & Development | 69.04M | 87.82M | 71.29M | 524.19M | 115.11M |
| Selling, General & Admin | 24.28M | 31.92M | 28.53M | 69.23M | 151.56M |
| Operating Expenses | 93.32M | 119.73M | 99.82M | 593.42M | 267.52M |
| Depreciation & Amortization | 184K | 199K | 222K | 683K | 1.74M |
| EBITDA | (86.66M) | (104M) | (75.58M) | (566.92M) | (189.21M) |
| EBITDA Margin | — | — | — | -7200.7% | -300.8% |
| Operating Income | (93.32M) | (119.73M) | (99.82M) | (592.63M) | (213.06M) |
| Operating Margin | — | — | — | -7527.3% | -338.7% |
| Interest Income | 2.96M | 7.45M | 24.61M | 27.06M | 21.43M |
| Interest Expense | 0 | 0 | 0 | 341K | 13.68M |
| Other Income / Expenses | 6.47M | 15.54M | 24.02M | 24.69M | 8.44M |
| Income Before Tax | (86.85M) | (104.2M) | (75.8M) | (567.94M) | (204.63M) |
| Pre-Tax Margin | — | — | — | -7213.8% | -325.3% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (86.85M) | (104.2M) | (75.8M) | (567.94M) | (204.63M) |
| Net Margin | — | — | — | -7213.8% | -325.3% |
| EPS (Basic) | (0.44) | (0.48) | (0.35) | (2.11) | (0.60) |
| EPS (Diluted) | (0.44) | (0.48) | (0.35) | (2.11) | (0.60) |
| Weighted Avg Shares | 197.89M | 216.72M | 218.88M | 268.77M | 341.54M |
| Weighted Avg Shares (Diluted) | 197.89M | 216.72M | 218.88M | 268.77M | 341.54M |
Nuvation Bio Inc.
NYSE:NUVB
Intrinsic Alpha fair value
Locked
Current Price
$3.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.